Myeloid/natural killer cell precursor acute leukemia (MNKPL) is a rare leukemia subtype characterized by a high incidence of extramedullary infiltration. No appropriate treatment strategy has so far been developed. Acute myelogenous leukemia-type chemotherapy combined with L-Asparaginase is an effective treatment for MNKPL. Hematopoietic cell transplantation is a second option in refractory cases.
Introduction
Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is a rare type of leukemia prevalent in Asia. MNKPL is a distinct entity in that it differs from myeloid/NK cell leukemia (MNKL) and blastic NK cell lymphoma/leukemia in terms of both morphology and immune type. MNKPL is characterized by marked extramedullary involvement, immature lymphoblastoid morphology without myeloperoxidase (MPO) reactivity, a CD7 
/CD34
À/+ phenotype, myeloid chemosensitivity, and a good prognosis. Because MNKPL is so rare, no appropriate therapeutic strategy has been established, making it hard to undertake systemic clinical trials. Therefore, accumulation of clinical observations and retrospective cohort studies will provide important information that can be used to develop future therapies.
Case Presentation
A 13-year-old Japanese boy presented to our hospital with fever, fatigue, and bilateral cervical lymphadenopathy. His Fig. 2A and B) . A lymph node biopsy also revealed massive infiltration by blast cells + ( Fig. 2A) . Immunohistochemical staining showed strong positivity for CD56, CD34, and BCL2, and moderate positivity for CD33 and MICA. Laboratory findings are shown in Table 1 .
The patient was diagnosed with MNKPL, for which there is no clinically evaluated chemotherapeutic strategy. A previous report suggests that acute myelogenous leukemia (AML)-type chemotherapy may be of benefit [1] , whereas other studies suggest that L-asparaginase (L-Asp) is effective against NK/T-cell-type lymphomas [2, 3] . Therefore, we used AML-type chemotherapy combined with L-Asp (10,000 U/m 2 9 5 times per cycle; five cycles in total). Induction chemotherapy led to complete remission (CR). However, the leukemia relapsed (ocular involvement) after two rounds of intensification chemotherapy [4] . After local ocular irradiation and four rounds of intensification treatment, second CR was achieved and the patient was discharged. However, 1 year after cessation of chemotherapy, pancytopenia and cervical lymph node swelling re-appeared. Bone marrow aspiration revealed bone marrow relapse. Therefore, the patient received idarubicin (IDA) combined with FLAG induction therapy, followed by one cycle of FLAG, Capizzi, and LDED intensification therapy. Second CR was again achieved. The patient then underwent hematopoietic cell transplantation (HCT) with 8/8 HLAmatched unrelated bone marrow. The conditioning regimen comprised total body irradiation (TBI; 12 Gy) and melphalan (60 mg/m 2 /day for 3 days). Tacrolimus (0.02 mg/kg/day) and methotrexate (MTX; 15 mg/m 2 on Day 1 and 10 mg/m 2 on Days 3, 6, and 11) were used for graft versus host disease (GVHD) prophylaxis. Engraftment was achieved by Day 21. Grade I GVHD was observed. Regimen-related toxicity was moderate. The patient stayed in remission for 2 years after HCT (Fig. 3) .
Discussion
Several case reports describing MNKPL have been published. It should be refrain that MNKPL is different entity to be distinguished from MNKL. MNKPL has a poor prognosis, whereas the prognosis for MNKL is much better. MNKPL is characterized by CD34 antigen-positivity and extramedullary involvement [1, 5] . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia does not mention MNKPL, but it may be categorized as AML with minimal differentiation or mixed phenotype acute leukemia, and not otherwise specified rare types (MPAL NOS rare types) [6] .
MNKPL shows a better therapeutic response to AML chemotherapy regimens than to ALL regimens [1] , and LAsp as a single agent is an effective treatment for relapsed/ refractory NK/T-cell lymphomas [2, 3] . Based on these observations, L-Asp has been incorporated into AML-type regimens used to treat several cases, including our own.
A literature review identified 13 pediatric (less than 20 years of age) MNKPL cases ( Table 2 ). The age of onset was between 0.9 and 19 years of age (mean, 8.3 years), and nine of 13 cases were male (69%). Six cases survived and were disease free (observation period, 24-63 months), and seven cases received AML-type chemotherapy during the induction, consolidation, or intensification phase. On the other hand, Guan et al. reported that the ALL-type regimen was effective in three MNKPL cases when using cytarabine, mitoxantrone, etoposide, (an agent used for the treatment of AML) and LAsp during the consolidation and intensification phases [7] . Among 13 pediatric cases, three cases received AMLtype chemotherapy combined with L-Asp, eight cases received allogenic HCT, and one case received autologous HCT. Among those who received allogenic HCT, two cases stayed in remission (observation period between 24 and 46 months). The three patients that received AMLtype chemotherapy combined with L-Asp (one of whom also received HCT) survived. In our case, initial chemotherapy comprised AML-type chemotherapy combined with L-Asp, followed by FLAG-IDA and a FLAG regimen (re-induction therapy) after relapse. A previous study reported that the FLAG regimen is an effective second-line therapy for MNKPL [8] . Our experience and previous observations suggest that AML-type chemotherapy combined with L-Asp is an effective treatment for MNKPL. A FLAG-based regimen might also be effective in refractory cases. We identified 14 adult cases ( Table 2) . Age of onset was between 21 and 63 years of age. Nine cases received myeloid-based chemotherapy, and three cases received HCT. Among those who received HCT, one case survived without disease free for more than 2 years. Among the seven cases without HCT, none survived. Our literature review did not clarify whether or not HCT benefits children in first remission. These observations suggest that, at least in adults, HCT must be performed in first remission.
The incidence of MNKPL is low. Therefore, no systemic clinical trial to develop an appropriate therapeutic approach has been undertaken. In this case, collection of case reports is essential. In addition, international collaborations will speed up progress toward developing a standard treatment plan.
